ClinicalTrials.gg
CompletedNCT02174159Updated Apr 10, 2023

Evaluation of Safety, Tolerability, Pharmacokinetics, and Antiretroviral Activity of Ulonivirine (MK-8507) in Human Immunodeficiency Virus (HIV-1)-Infected Participants (MK-8507-003)

A Phase 1 interventional study of Ulonivirine in HIV-1 Infection, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2023-04-10.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Non-randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

The study will evaluate the safety, tolerability, pharmacokinetics, and antiretroviral activity of a single dose of ulonivirine in antiretroviral therapy (ART)-naive, HIV-1 infected participants. The hypothesis tested in the study is that at a safe and well-tolerated dose, ulonivirine has superior antiretroviral activity to a historical placebo control, as measured by change from baseline in plasma HIV-1 ribonucleic acid (RNA) at 168 hours postdose.

02

Conditions studied

  • HIV-1 Infection
03

In context

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male, or non-pregnant and non-breastfeeding female, or or surgically sterile female (confirmed with medical records, examination, or laboratory test). Male participants with female partner of agrees to use a medically acceptable method of during the study and 90 days after receiving study drug.
  • \<=35 kg/m\^2
  • Other than infection, baseline health judged to be stable at screening and/or prior to administration of study drug
  • No clinically-significant abnormality
  • Documented to be HIV-1 positive as determined by a positive enzyme-linked immunosorbent assay (ELISA) or quantitative polymerase chain reaction (PCR) result with confirmation
  • Has a screening plasma Cluster of Differentiation (CD4) T-cell count of >200 /mm\^3
  • Has a plasma HIV-1 RNA >= 10,000 copies/mL within 30 days before administration of study drug
  • ART-naive, defined as never having received any ART agent, or have received \<=30 consecutive days of an ART agent, excluding non-nucleoside reverse transcriptase inhibitors (NNRTIs), or have received \<=60 consecutive days of combination ART, excluding NNRTIs
  • Has not received an investigational agent or licensed ART within 30 days of study drug administration
  • Diagnosed with HIV-1 infection >=3 months before screening
  • Willing to receive no other ART for the duration of the study
  • Has no evidence of mutations conferring resistance to NNRTIs at screening

Exclusion criteria

Exclusion Criteria:

  • Mentally or legally institutionalized or incapacitated, has significant emotional problems, or has a history of psychiatric disorder
  • History of clinically significant and not stably controlled abnormalities or diseases
  • History of cancer, with the exceptions of 1) adequately-treated non-melanomatous skin carcinoma or carcinoma in situ of the cervix, 2) other which have been successfully treated >=10 years before screening, or 3) participants who are highly unlikely to sustain a recurrence for the duration of the study
  • History of significant multiple and/or severe allergies, or has had an anaphylactic reaction or significant intolerability to drugs or food
  • Positive for surface antigen
  • History of chronic virus (HCV) unless there has been a documented cure or a negative HCV viral load
  • Had major surgery, or donated or lost >=1 unit (\~500 mL) of blood within 4 weeks before screening
  • Participated in another trial within 4 weeks before administration of study drug
  • Unable to refrain from or anticipates the use of any medication beginning 4 weeks before administration of study drug and throughout the trial. Certain medications are permitted.
  • Consumes >3 glasses of alcoholic beverages per day (1 glass is equivalent to 12 ounces of beer, 4 ounces of wine, or 1 ounce of distilled spirits). Participants who consume 4 glasses of alcoholic beverages per day may be enrolled at the discretion of the investigator.
  • Consumes >10 cigarettes per day and is unwilling to restrict smoking to \<=10 cigarettes per day
  • Regular user of any illicit drugs or has a history of drug abuse (including alcohol) within 2 years
  • Has an immediate family member who is investigational site or sponsor staff directly involved with the trial
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    Panel A: Ulonivirine 600 mg

    Single oral dose of ulonivirine 600 mg (supplied as 10 mg and 100 mg tablets) administered after an overnight fast

    Drug: Ulonivirine

  • Experimental
    Panel B: Ulonivirine 150 mg

    Single oral dose of ulonivirine 150 mg (supplied as 10 mg and 100 mg tablets) administered after an overnight fast

    Drug: Ulonivirine

  • Experimental
    Panel C: Ulonivirine <=600 mg

    Single oral dose of ulonivirine \<=600 mg mg (supplied as 10 mg and 100 mg tablets) administered after an overnight fast. Inclusion of Panel C in the study, and the dose selected, will be decided pending evaluation of results for Panels A and B.

    Drug: Ulonivirine

Interventions

  • MK-8507 administered as a single oral dose

    Also known as: MK-8507

06

What researchers measure

Primary outcomes

  1. Change from Baseline in Plasma HIV-1 RNA

    Time frame: 168 hours (7 days) postdose

  2. Number of Participants with One or More Adverse Experiences

    Time frame: Up to 21 days postdose

Secondary outcomes

  1. Area Under the Plasma Concentration-Time Curve of Ulonivirine (AUC0-168hr)

    Time frame: Up to 168 hours postdose

  2. Maximum Plasma Concentration of Ulonivirine (Cmax)

    Time frame: Up to 336 hours postdose

  3. Time of Maximum Plasma Concentration of Ulonivirine (Tmax)

    Time frame: Up to 336 hours postdose

  4. Plasma Concentration of Ulonivirine at 168 Hours Postdose (C168hr)

    Time frame: 168 hours postdose

  5. Plasma Concentration of Ulonivirine at 336 Hours Postdose (C336hr)

    Time frame: 336 hours postdose

  6. Apparent Terminal Half-Life (T1/2) of Plasma Ulonivirine

    Time frame: Up to 336 hours postdose

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Schurmann D, Jackson Rudd D, Schaeffer A, De Lepeleire I, Friedman EJ, Robberechts M, Zhang S, Liu Y, Kandala B, Keicher C, Daumer M, Hofmann J, Grobler JA, Stoch SA, Iwamoto M, Ankrom W. Single Oral Doses of MK-8507, a Novel Non-Nucleoside Reverse Transcriptase Inhibitor, Suppress HIV-1 RNA for a Week. J Acquir Immune Defic Syndr. 2022 Feb 1;89(2):191-198. doi: 10.1097/QAI.0000000000002834. PubMed 34654041 ↗

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2014 to primary completion in Jul 2015, 10 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 24, 2014
First posted
Jun 25, 2014
StartActual
Sep 15, 2014
Primary completionActual
Jul 16, 2015
CompletionActual
Jul 23, 2015
Last update
Apr 10, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 10, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02174159
Responsible party
Sponsor
First posted
Jun 25, 2014
Start date
Sep 15, 2014
Primary completion
Jul 16, 2015
Completion
Jul 23, 2015
Last update
Apr 10, 2023

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ulonivirine

Start the discussion